A case report in Japan shows Spinraza helped a boy with SMA type 0 sit without support for a short time at age 2 and stand ...

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

SMA patients who can sit see improvements in motor function over 12 months of treatment with DMTs, particularly in fine motor ...

treatment Spinraza (nusinersen). The proposed higher dose regimen includes two 50mg doses administered 14 days apart, followed by a maintenance dose of 28mg every four months. This is fewer doses ...

In the US, a single shot of Zolgensma (onasemnogene abeparvovec) costs $2.1 million, while Spinraza (nusinersen) costs $750,000 in its first year. Biogen said it aims to begin a phase IV study as ...

This is in contrast to the approved 12 mg regimen of SPINRAZA, the brand name under which nusinersen is currently commercialized in over 71 countries. The applications for the updated dosing ...

Nusinersen is currently commercialized under the brand name SPINRAZA in over 71 countries at the label-approved dose of 12 mg. “Continued progress to improve upon the remarkable initial ...

The STRENGTH study found OAV101 IT stabilized motor function in patients who had discontinued Spinraza or Evrysdi ... who had discontinued treatment with nusinersen or risdiplam.

Each take home $3 million. Molecular geneticist Adrian Krainer of Cold Spring Harbor Laboratory received the award for his part in developing nusinersen (Spinraza), an oligonucleotide therapeutic for ...